Please login to the form below

Not currently logged in

Call for genetic tests to bring personalised medicine to children with cancer

Action needed as childhood cancer survival has plateaued

All children with cancer should have the genetic profile of their tumour comprehensively analysed when being considered for new treatments, say leading UK childhood cancer experts.

Leading scientists and doctors are calling for a major upscaling in genetic sequencing for children with cancer, to understand patients’ disease better and help direct them to clinical trials that could offer more precise treatment. They also believe this genetic information could help drive the discovery of new targeted treatments for childhood cancers.

NHS England plans to introduce an NHS Genomic Medicine Service shortly to begin putting in place the resources and infrastructure to expand access to sequencing.

Experts at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust want the NHS to dramatically scale up access to genetic sequencing for children, so that doctors can routinely carry out sequencing in children at all stages in their treatment, and especially at relapse.

They say new funding and changes in clinical practice can turn the promise of the NHS Genomic Medicine Service into reality. Their call is being timed for Children’s Cancer Awareness Month, to maximise the chances that governments across the UK will listen.

Louis Chesler

Professor Louis Chesler

Professor Louis Chesler, Professor of Paediatric Solid Tumour Therapeutics at The Institute of Cancer Research, London, and Consultant in Paediatric Oncology at The Royal Marsden NHS Foundation Trust, said:

“Molecular profiling of children’s cancers will be incredibly useful when it comes to finding new treatments. We may be able to increase the chance of a child responding to treatment by looking for genetic changes in their tumour that can be targeted using existing drugs. If no drugs exist, this will highlight areas for future scientific discovery, which is what drives the development of new, more effective treatments.

“We urgently need to ensure that the infrastructure is in place to analyse all these samples and to return useful information to clinicians that can guide treatment.”

The molecular profile of a child’s tumour, which includes genetic information about the cancer, is currently only assessed in sufficient detail at diagnosis at a few specialist paediatric centres in the UK and, till very recently, very rarely sufficiently studied at relapse. The situation is better in some other parts of Europe and the US.

Around 1,800 children (aged 14 or under) are diagnosed with cancer in the UK each year. Childhood cancer survival has plateaued and an insufficient number of the new targeted drugs that attack cancer-causing genes have been made available for testing in children.

Scientists at The Institute of Cancer Research (ICR) and paediatric oncologists at The Royal Marsden argue that it is important to obtain genetic information at relapse even if it has already been obtained at diagnosis, as many tumours evolve and become more aggressive and resistant to treatment over time, and new mutations may arise.

The plea for more funding and a change in clinical practice comes just days after a group of expert centres in London unveiled plans for a ‘powerhouse’ of cancer research.

Article by
Andrew McConaghie

27th September 2018

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...